tiprankstipranks
Elevance Health (ELV)
NYSE:ELV
US Market
ELV
Elevance Health
RESEARCH TOOLSreports

Elevance Health (ELV) Stock Forecast & Price Target

2,885 Followers
See the Price Targets and Ratings of:

ELV Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
12 Buy
5 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ELV Stock 12 Month Forecast

Average Price Target

$382.24
▲(27.10% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $382.24 with a high forecast of $425.00 and a low forecast of $332.00. The average price target represents a 27.10% change from the last price of $300.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"269":"$269","426":"$426","308.25":"$308.3","347.5":"$347.5","386.75":"$386.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":425,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$425.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":382.24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$382.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":332,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$332.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[269,308.25,347.5,386.75,426],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.5,308.2307692307692,317.96153846153845,327.6923076923077,337.4230769230769,347.15384615384613,356.88461538461536,366.61538461538464,376.3461538461538,386.0769230769231,395.80769230769226,405.53846153846155,415.2692307692308,{"y":425,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.5,304.94153846153847,311.38307692307694,317.8246153846154,324.2661538461538,330.7076923076923,337.14923076923077,343.59076923076924,350.0323076923077,356.4738461538462,362.9153846153846,369.35692307692307,375.79846153846154,{"y":382.24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,298.5,301.0769230769231,303.65384615384613,306.2307692307692,308.8076923076923,311.38461538461536,313.96153846153845,316.53846153846155,319.11538461538464,321.6923076923077,324.2692307692308,326.84615384615387,329.4230769230769,{"y":332,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":423.634,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":399.774,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":369.167,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.194,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":270.103,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.363,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":328.926,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":313.64,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":348.402,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":339.735,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":292.268,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$425.00Average Price Target$382.24Lowest Price Target$332.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$350
Hold
16.38%
Upside
Reiterated
03/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (NASDAQ: DMAC), Elevance Health (NYSE: ELV) and Oric Pharmaceuticals (NASDAQ: ORIC)
Bernstein Analyst forecast on ELV
Lance Wilkes
Bernstein
Bernstein
$384
Buy
27.69%
Upside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and Elevance Health (NYSE: ELV)
Cantor Fitzgerald Analyst forecast on ELV
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$400
Buy
33.01%
Upside
Reiterated
03/24/26
Cantor Fitzgerald Sticks to Its Buy Rating for Elevance Health (ELV)
Mizuho Securities Analyst forecast on ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$413→$350
Buy
16.38%
Upside
Reiterated
03/11/26
Elevance Health price target lowered to $350 from $413 at MizuhoElevance Health price target lowered to $350 from $413 at Mizuho
Barclays Analyst forecast on ELV
Andrew Mok CFA
Barclays
Barclays
$393
Buy
30.68%
Upside
Reiterated
03/11/26
Barclays Reaffirms Their Buy Rating on Elevance Health (ELV)
Wells Fargo Analyst forecast on ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$391
Buy
30.01%
Upside
Reiterated
03/03/26
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Veeva Systems (NYSE: VEEV) and Janux Therapeutics Inc (NASDAQ: JANX)
RBC Capital Analyst forecast on ELV
Ben Hendrix
RBC Capital
RBC Capital
$392→$358
Hold
19.04%
Upside
Downgraded
02/03/26
Elevance Health downgraded to Sector Perform from Outperform at RBC CapitalElevance Health downgraded to Sector Perform from Outperform at RBC Capital
Truist Financial Analyst forecast on ELV
David S Macdonald
Truist Financial
Truist Financial
$400→$390
Buy
29.68%
Upside
Reiterated
02/02/26
Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)
J.P. Morgan Analyst forecast on ELV
Lisa Gill
J.P. Morgan
J.P. Morgan
$394→$397
Buy
32.01%
Upside
Reiterated
02/02/26
Elevance Health price target raised to $397 from $394 at JPMorganElevance Health price target raised to $397 from $394 at JPMorgan
TD Cowen Analyst forecast on ELV
Ryan Langston
TD Cowen
TD Cowen
$400
Buy
33.01%
Upside
Reiterated
02/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Elevance Health (NYSE: ELV)
Jefferies Analyst forecast on ELV
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$395
Buy
31.34%
Upside
Reiterated
01/30/26
Jefferies Remains a Buy on Elevance Health (ELV)
Morgan Stanley Analyst forecast on ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$352
Hold
17.04%
Upside
Reiterated
01/29/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Halozyme (NASDAQ: HALO) and Elevance Health (NYSE: ELV)
UBS Analyst forecast on ELV
A.J. Rice
UBS
UBS
$425→$400
Buy
33.01%
Upside
Reiterated
01/29/26
Elevance Health price target lowered to $400 from $425 at UBSElevance Health price target lowered to $400 from $425 at UBS
Deutsche Bank Analyst forecast on ELV
George Hill
Deutsche Bank
Deutsche Bank
$320→$332
Hold
10.39%
Upside
Reiterated
01/29/26
Elevance Health price target raised to $332 from $320 at Deutsche BankElevance Health price target raised to $332 from $320 at Deutsche Bank
Bank of America Securities Analyst forecast on ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$385
Hold
28.02%
Upside
Reiterated
01/29/26
Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (NASDAQ: CRVS), Elevance Health (NYSE: ELV) and Universal Health (NYSE: UHS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on ELV
Scott Fidel
Goldman Sachs
Goldman Sachs
$350
Hold
16.38%
Upside
Reiterated
03/31/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Diamedica Therapeutics (NASDAQ: DMAC), Elevance Health (NYSE: ELV) and Oric Pharmaceuticals (NASDAQ: ORIC)
Bernstein Analyst forecast on ELV
Lance Wilkes
Bernstein
Bernstein
$384
Buy
27.69%
Upside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and Elevance Health (NYSE: ELV)
Cantor Fitzgerald Analyst forecast on ELV
Sarah James
Cantor Fitzgerald
Cantor Fitzgerald
$400
Buy
33.01%
Upside
Reiterated
03/24/26
Cantor Fitzgerald Sticks to Its Buy Rating for Elevance Health (ELV)
Mizuho Securities Analyst forecast on ELV
Ann Hynes
Mizuho Securities
Mizuho Securities
$413→$350
Buy
16.38%
Upside
Reiterated
03/11/26
Elevance Health price target lowered to $350 from $413 at MizuhoElevance Health price target lowered to $350 from $413 at Mizuho
Barclays Analyst forecast on ELV
Andrew Mok CFA
Barclays
Barclays
$393
Buy
30.68%
Upside
Reiterated
03/11/26
Barclays Reaffirms Their Buy Rating on Elevance Health (ELV)
Wells Fargo Analyst forecast on ELV
Stephen Baxter
Wells Fargo
Wells Fargo
$391
Buy
30.01%
Upside
Reiterated
03/03/26
Analysts Offer Insights on Healthcare Companies: Elevance Health (NYSE: ELV), Veeva Systems (NYSE: VEEV) and Janux Therapeutics Inc (NASDAQ: JANX)
RBC Capital Analyst forecast on ELV
Ben Hendrix
RBC Capital
RBC Capital
$392→$358
Hold
19.04%
Upside
Downgraded
02/03/26
Elevance Health downgraded to Sector Perform from Outperform at RBC CapitalElevance Health downgraded to Sector Perform from Outperform at RBC Capital
Truist Financial Analyst forecast on ELV
David S Macdonald
Truist Financial
Truist Financial
$400→$390
Buy
29.68%
Upside
Reiterated
02/02/26
Truist Financial Sticks to Its Buy Rating for Elevance Health (ELV)
J.P. Morgan Analyst forecast on ELV
Lisa Gill
J.P. Morgan
J.P. Morgan
$394→$397
Buy
32.01%
Upside
Reiterated
02/02/26
Elevance Health price target raised to $397 from $394 at JPMorganElevance Health price target raised to $397 from $394 at JPMorgan
TD Cowen Analyst forecast on ELV
Ryan Langston
TD Cowen
TD Cowen
$400
Buy
33.01%
Upside
Reiterated
02/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Elevance Health (NYSE: ELV)
Jefferies Analyst forecast on ELV
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$395
Buy
31.34%
Upside
Reiterated
01/30/26
Jefferies Remains a Buy on Elevance Health (ELV)
Morgan Stanley Analyst forecast on ELV
Erin Wright
Morgan Stanley
Morgan Stanley
$352
Hold
17.04%
Upside
Reiterated
01/29/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Halozyme (NASDAQ: HALO) and Elevance Health (NYSE: ELV)
UBS Analyst forecast on ELV
A.J. Rice
UBS
UBS
$425→$400
Buy
33.01%
Upside
Reiterated
01/29/26
Elevance Health price target lowered to $400 from $425 at UBSElevance Health price target lowered to $400 from $425 at UBS
Deutsche Bank Analyst forecast on ELV
George Hill
Deutsche Bank
Deutsche Bank
$320→$332
Hold
10.39%
Upside
Reiterated
01/29/26
Elevance Health price target raised to $332 from $320 at Deutsche BankElevance Health price target raised to $332 from $320 at Deutsche Bank
Bank of America Securities Analyst forecast on ELV
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$385
Hold
28.02%
Upside
Reiterated
01/29/26
Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (NASDAQ: CRVS), Elevance Health (NYSE: ELV) and Universal Health (NYSE: UHS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
xxx
Success Rate
10/16 ratings generated profit
63%
Average Return
+2.04%
reiterated a xxx
 rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +2.04% per trade.
1 Year
A.J. RiceUBS
Success Rate
20/31 ratings generated profit
65%
Average Return
+14.56%
reiterated a buy rating 2 months ago
Copying A.J. Rice's trades and holding each position for 1 Year would result in 64.52% of your transactions generating a profit, with an average return of +14.56% per trade.
2 Years
xxx
Success Rate
24/31 ratings generated profit
77%
Average Return
+35.93%
reiterated a xxx
 rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 77.42% of your transactions generating a profit, with an average return of +35.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ELV Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
31
26
28
27
10
Hold
23
29
25
43
33
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
55
53
70
43
In the current month, ELV has received 10 Buy Ratings, 33 Hold Ratings, and 0 Sell Ratings. ELV average Analyst price target in the past 3 months is 382.24.
Each month's total comprises the sum of three months' worth of ratings.

ELV Financial Forecast

ELV Earnings Forecast

Next quarter’s earnings estimate for ELV is $10.74 with a range of $6.53 to $11.53. The previous quarter’s EPS was $3.33. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ELV is $10.74 with a range of $6.53 to $11.53. The previous quarter’s EPS was $3.33. ELV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Sales Forecast

Next quarter’s sales forecast for ELV is $48.21B with a range of $45.78B to $51.83B. The previous quarter’s sales results were $49.75B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.
Next quarter’s sales forecast for ELV is $48.21B with a range of $45.78B to $51.83B. The previous quarter’s sales results were $49.75B. ELV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ELV has Performed in-line its overall industry.

ELV Stock Forecast FAQ

What is ELV’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 382.24.
    What is ELV’s upside potential, based on the analysts’ average price target?
    Elevance Health has 27.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ELV a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Moderate Buy which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Elevance Health’s price target?
            The average price target for Elevance Health is 382.24. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $425.00 ,the lowest forecast is $332.00. The average price target represents 27.10% Increase from the current price of $300.74.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of ELV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.